Understand the source comparison
Tesofensine Appetite Control Research: Comparison
Tesofensine 1.0mg Triple reuptake inhibitor (serotonin, dopamine, norepinephrine) 12.8% vs 2.0% placebo Central (hypothalamic). Enhances satiety signaling and reduces reward value of food +6–10% increase in resting energy expenditure Strongest single-agent app
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Tesofensine 1.0mg
- Triple reuptake inhibitor (serotonin, dopamine, norepinephrine)
- 12.8% vs 2.0% placebo
- Central (hypothalamic). Enhances satiety signaling and reduces reward value of food
- +6–10% increase in resting energy expenditure
- Strongest single-agent appetite effect recorded in Phase III obesity trials. Central mechanism avoids gastric side effects but carries cardiovascular monitoring requirement
- Semaglutide 2.4mg (Wegovy)
- GLP-1 receptor agonist
- 14.9% vs 2.4% placebo
- Peripheral (gastric). Slows gastric emptying and delays ghrelin rebound
- Neutral to slightly negative (NEAT reduction in some cohorts)
- Comparable weight loss to tesofensine but via peripheral satiety mechanism. GI side effects (nausea, vomiting) occur in 30–45% during titration
- Phentermine 37.5mg
- Norepinephrine reuptake inhibitor + releaser
- 6–8% vs 1–2% placebo
- Single pathway (noradrenergic only)
- +4–6% increase in metabolic rate
- Lower efficacy than tesofensine due to single-pathway mechanism. Tolerance develops within 8–12 weeks in most patients
- Liraglutide 3.0mg (Saxenda)
- GLP-1 receptor agonist (earlier generation)
- 8.0% vs 2.6% placebo
- Peripheral (gastric). Slows gastric emptying
- Neutral
- Lower potency than semaglutide. Daily injection requirement vs weekly for semaglutide. Similar GI side effect profile